CARDIOTOXICITY IN METASTATIC RENAL CELL CARCINOMA (mRCC) PATIENTS TREATED WITH SUNITINIB (SU)

被引：0
|
作者：
Ballatore, Valentina [1 ]
Prati, Veronica [1 ]
Ruatta, Fiorella [1 ]
Galizia, Danilo [1 ]
Grignani, Giovanni [1 ]
Aglietta, Massimo [1 ]
Ortega, Cinzia [1 ]
机构：
[1] Oncol Med Fdn Piemonte Oncol, Ist Ric & Cura Cancro Candiolo, Turin, Italy
来源：
ANTICANCER RESEARCH | 2012年 / 32卷 / 05期
关键词：
CARDIOVASCULAR TOXICITY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
49
引用
收藏
页码：1876 / 1877
页数：2
相关论文
共 50 条
  • [21] Relation between lactate dehydrogenase (LDH) during two first cycles in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU)
    Medioni, J.
    Arakelian, N.
    Fournier, L.
    Helley, D.
    Thiam, R.
    Banu, E.
    Cuenod, C.
    Oudard, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Response of renal lesions in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib - a single center retrospective analysis
    Seidel, C.
    Fenner, M.
    Reuter, C.
    Ivanyi, P.
    Ganser, A.
    Gruenwald, V.
    EJC SUPPLEMENTS, 2009, 7 (02): : 438 - 438
  • [23] Immune cell changes in the peripheral blood of metastatic renal cell carcinoma (mRCC) patients (pts) treated with sunitinib or temsirolimus
    Salas, R. N.
    Ireland, J. L.
    Ko, J. S.
    Elson, P.
    Garcia, J. A.
    Wood, L.
    Bukowski, R. M.
    Rini, B. I.
    Finke, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Association of tumor burden characteristics with outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib
    Golshayan, A. R.
    Elson, P.
    Wood, L. S.
    Garcia, J. A.
    Dreicer, R.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] Biological toxicity as a predictive factor of efficacy in metastatic renal cell carcinoma (mRCC) treated with sunitinib
    Guillabert, P.
    Elaidi, R. T.
    Teghom, C.
    Medioni, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S651 - S651
  • [26] Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
    Rini, Brian I.
    Tamaskar, Ila
    Shaheen, Phillip
    Salas, Renee
    Garcia, Jorge
    Wood, Laura
    Reddy, Sethu
    Dreicer, Robert
    Bukowski, Ronald M.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (01): : 81 - 83
  • [27] SUNITINIB AND SORAFENIB THERAPY FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (mRCC): SAFETY PROFILE
    Massari, Francesco
    Cricca, Antonia
    Sperandi, Francesca
    Martoni, Andrea Angelo
    ANTICANCER RESEARCH, 2010, 30 (04) : 1379 - 1380
  • [28] Metformin (met) use and outcome of sunitinib (Su) treatment (tx) in diabetic patients (pts) with metastatic renal cell carcinoma (mRCC)
    Keizman, Daniel
    Ish-Shalom, Maya
    Peer, Avivit
    Chish, Adi
    Sella, Avishay
    Gottfried, Maya
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Neiman, Victoria
    Rosenbaum, Eli
    Sarid, David
    Gez, Eliahu
    Mermershtain, Wilmosh
    Rouvinov, Keren
    Weitzen, Rony
    Weitzen, Rony
    Berger, Raanan
    Carducci, Michael Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC).
    Ronnen, E. A.
    Kondagunta, G. V.
    Lau, C.
    Fischer, P.
    Ginsberg, M. S.
    Baum, M.
    Kim, S. T.
    Chen, I.
    Baum, C. M.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 225S - 225S
  • [30] Efficacy and safety of sunitinib (SU) in patients (pts) with metastatic renal cell carcinoma (mRCC) and lung metastases (mets) only at baseline
    Shinohara, Nobuo
    Akaza, Hideyuki
    Tomita, Yoshihiko
    Yuasa, Takeshi
    Fujimoto, Hiroyuki
    Niwakawa, Masashi
    Ozono, Seiichiro
    Mugiya, Soichi
    Miki, Tsuneharu
    Uemura, Hirotsugu
    Nonomura, Norio
    Takahashi, Masayuki
    Hasegawa, Yoshihiro
    Ueda, Eiji
    Shibata, Atsushi
    Kawai, Norisuke
    Naito, Seiji
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345